Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts

Strategic Refocus:
Amgen has made significant cuts to its pipeline but remains committed to its obesity initiatives, emphasizing the development of obesity-related treatments.

MariTide Program:
The company is preparing to launch a broad Phase 3 program for MariTide, targeting obesity, obesity-related conditions, and Type 2 diabetes.

Obesity as a Priority:
Despite the pipeline cuts, Amgen's focus on obesity reflects the global health challenge posed by obesity and its related illnesses, such as heart and respiratory diseases.

Diverse Treatment Approaches:
Amgen's obesity initiatives include various therapeutic approaches tailored to meet the dynamic needs of individuals living with obesity.

Global Health Impact:
Obesity affects approximately one billion people worldwide, with numbers expected to rise, underscoring the importance of Amgen's focus on this area.